Quotient Ltd(NASDAQ:QTNT) announced the earnings results for Fiscal Year 2017 and Q3. The results came in during After-Market on Feb 6, 2017. Company reported revenue of $4.841M. Analysts estimated a revenue of $4.550M. The revenues were 6.4% above the estimates. Earnings per share were $-1.06. The reported EPS was below estimates by -89.29%. Analysts had estimated an EPS of $-0.56.
Quotient Ltd (QTNT) made into the market gainers list on Tuesdays trading session with the shares advancing 4.51% or 0.3 points. Due to strong positive momentum, the stock ended at $6.95, which is also near the day’s high of $7.05. The stock began the session at $6.5 and the volume stood at 88,886 shares. The 52-week high of the shares is $12.96 and the 52 week low is $3.75. The company has a current market capitalization of $205 M and it has 2,95,03,784 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Aug 5, 2016, Zubeen Shroff (director 10% owner) purchased 180,000 shares at $5.50 per share price.Also, On Aug 5, 2016, L John Wilkerson (director 10% owner) purchased 180,000 shares at $5.50 per share price.On Aug 4, 2016, D J Paul E Cowan (director officer 10% owner ) purchased 45,455 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens. The Company is engaged in the development manufacturing and commercialization of conventional reagent products for blood grouping. The Company also undertakes product development projects for its original equipment manufacturer (OEM) customers. The Company develops manufactures and commercializes the products including Antisera products Reagent Red Blood Cells Whole Blood Controls and Ancillary products. The Company is developing MosaiQ to characterize donor and patient blood and serologically screen donor blood for specific viruses.